共 50 条
- [31] Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted TherapyCLINICAL CANCER RESEARCH, 2024, 30 (19) : 4491 - 4504Gonzalez-Medina, AlbertoVila-Casadesus, MariaGomez-Rey, MarinaFabregat-Franco, CarlesSierra, AlexandreTian, Tian V.Castet, FlorianCastillo, GloriaMatito, JuditMartinez, PaolaMiquel, Josep M.Nuciforo, PaoloPerez-Lopez, RaquelMacarulla, TeresaVivancos, Ana
- [32] Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological studyVIRCHOWS ARCHIV, 2024, 484 (06) : 915 - 923Sasaki, MotokoSato, YasunoriNakanuma, Yasuni
- [33] Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Shroff, Rachna T.Rearden, JessicaLi, AiMoran, SusanShepherd, Stacie PeacockLamarca, Angela
- [34] Integrative network propagation to uncover potential drug resistance mechanisms in FGFR2 fusion-positive cholangiocarcinomaCANCER RESEARCH, 2020, 80 (16)Hwang, YeonjooSwaney, Danielle L.Bardeesy, NabeelGordan, John D.
- [35] FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISHVIRCHOWS ARCHIV, 2025,Zhang, XinBai, QianmingWang, YulinJiang, ZhengzengHan, JingXue, ChengHuang, KaiLuan, LijuanHuang, XiaoyongHuang, XiaowuShi, GuomingHou, YingyongJi, Yuan
- [36] Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusionMOLECULAR CANCER, 2024, 23 (01)He, Guo-qianLi, QingJing, Xiao-yuLi, JianGao, JuGuo, Xia
- [37] Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case ReportONCOTARGETS AND THERAPY, 2024, 17 : 489 - 496d'Arienzo, Paolo D.MacDonald, Alan R.Patel, VirjenMa, Yuk T.Pihlak, RilleStarling, Naureen
- [38] A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinomaMOLECULAR THERAPY NUCLEIC ACIDS, 2023, 34Chu, ZhenzhenZhang, BaohuanZhou, XuxuanYuan, HuiGao, ChongqingLiu, LihaoXiao, YangZhang, JichunHong, JianLiang, JunjieChen, DongYao, Nan
- [39] Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinomaNature Communications, 6Daniela SiaBojan LosicAgrin MoeiniLaia CabellosKe HaoKate RevillDennis BonalOriana MiltiadousZhongyang ZhangYujin HoshidaHelena CornellaMireia Castillo-MartinRoser PinyolYumi KasaiSasan RoayaieSwan N. ThungJosep FusterMyron E. SchwartzSamuel WaxmanCarlos Cordon-CardoEric SchadtVincenzo MazzaferroJosep M. Llovet
- [40] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumorsCANCER RESEARCH, 2019, 79 (13)Li, GaryKrook, MelanieRoychowdhury, SameekAvogadri, FrancescaYe, YiningMoran, Susan